Company Overview and News

48
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

2018-06-18 zacks
Chicago, IL – June 18, 2018 – Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Boston Scientific (BSX - Free Report) , Stryker Corporation (SYK - Free Report) , Medtronic (MDT - Free Report) , Abbott (ABT - Free Report) and Varian Medical (VAR - Free Report) .
SRX ELY SXMDF SAPGF ENSG SRXTY GIII MDT SAP BSX IFNNY SYK KMG IFNNF DLA

166
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

2018-06-16 zacks
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry’s lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.
IFK TGTX NXTM SRXTY BAX OSUR 1302 BSX SYK INSY CAH SRX SXMDF IFX ISRG HSIC 0165 MDT EGRX FTV JNJ SRDX ABMD ROSA

162
Chinese ride-sharing giant Didi picks Australia for first Western foray

2018-06-15 malaymail
SYDNEY, June 15 — Didi Chuxing Technology Co Ltd, the Chinese ride-sharing company that bought the mainland operations of Uber Technologies Inc, will begin offering its service this month in Australia, its first foray in a Western-style country.
SRX SXMDF VAR AAPL SRXTY 9984 SFTBF SFTBY

6
Chinese ride-sharing giant Didi picks Australia for first Western foray

2018-06-15 theage.com.au
Didi Chuxing Technology Co, the Chinese ride-sharing company that bought the mainland operations of Uber Technologies, says it will begin offering its service this month in Australia, its first foray in a Western country.
SRX SXMDF VAR SRXTY 9984 SFTBF SFTBY

0
Donald Trump unlikely to turn away $1.9b Chinese bid, says Sirtex boss

2018-06-15 theage.com.au
Donald Trump’s diplomatic tensions with China are unlikely to stop regulatory approval of the $1.9 billion takeover deal headed by China's CDH Investments of Sirtex Medical, says chief executive Andrew McLean.
SRX SXMDF SRXTY

4
Sirtex agrees to takeover by China's CDH

2018-06-15 perthnow.com.au
Liver cancer treatment developer Sirtex Medical has accepted a $1.87 billion takeover bid from China's CDH Genetech after another suitor, Varian Medical Systems of the US, declined to match or beat CDH's offer.
SRX SXMDF VAR SRXTY

6
Chinese ride-sharing giant Didi picks Australia for first Western foray

2018-06-15 smh.com.au
Didi Chuxing Technology Co, the Chinese ride-sharing company that bought the mainland operations of Uber Technologies, says it will begin offering its service this month in Australia, its first foray in a Western country.
SRX SXMDF VAR SRXTY 9984 SFTBF SFTBY

0
Donald Trump unlikely to turn away $1.9b Chinese bid, says Sirtex boss

2018-06-15 smh.com.au
Donald Trump’s diplomatic tensions with China are unlikely to stop regulatory approval of the $1.9 billion takeover deal headed by China's CDH Investments of Sirtex Medical, says chief executive Andrew McLean.
SRX SXMDF SRXTY

6
Chinese ride-sharing giant Didi picks Australia for first Western foray

2018-06-15 channelnewsasia
SYDNEY/SHANGHAI: Didi Chuxing Technology, the Chinese ride-sharing company that bought the mainland operations of Uber Technologies, will begin offering its service this month in Australia, its first foray in a Western-style country.
SRX SXMDF VAR SRXTY 9984 SFTBF SFTBY

86
Deals of the day-Mergers and acquisitions

2018-06-14 reuters
June 14 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Thursday:
MNLDF FOX SRX SXMDF CCV CMCSA RCL SRXTY CCZ 532843 MDL ERA HMBH ABCB VAR FORTIS CCV.CL FORTISMLR FOXA CMCSK 523696 DIS

0
Sirtex Medical goodbyes Varian, backs $1.9b Chinese offer from CDH

2018-06-14 theage.com.au
Sirtex Medical’s board has announced it is backing China's CDH Investments' $1.9 billion bid for the medical device maker, which it thinks will help it manoeuvre into the potentially lucrative Chinese market.
SRX SXMDF SRXTY

0
Sirtex Medical goodbyes Varian, backs $1.9b Chinese offer from CDH

2018-06-14 smh.com.au
Sirtex Medical’s board has announced it is backing China's CDH Investments' $1.9 billion bid for the medical device maker, which it thinks will help it manoeuvre into the potentially lucrative Chinese market.
SRX SXMDF SRXTY

0
Varian asks court to allow Sirtex shareholders consider takeover bid

2018-05-28 theage.com.au
US cancer treatment developer Varian is seeking a Federal Court order to allow shareholders to consider its proposed takeover bid for Australian biotechnology company Sirtex Medical.
SRX SXMDF SRXTY

0
Varian asks court to allow Sirtex shareholders consider takeover bid

2018-05-28 smh.com.au
US cancer treatment developer Varian is seeking a Federal Court order to allow shareholders to consider its proposed takeover bid for Australian biotechnology company Sirtex Medical.
SRX SXMDF SRXTY

23
'Clock is ticking': Private equity ready to pounce on deals

2018-05-25 theage.com.au
Several top Australian companies have received and rejected takeover offers this year but that isn't likely to deter dealmaking, especially from private equity.
BAMGF SRX SXMDF VAR SRXTY BAMKF BAM

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

20h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

20h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...